Shuaizhijia Group's internally developed regulatory affairs platform, RegPath Navigator, completed beta testing on March 15 and is now in production use. The first 5 onboarded projects cover prescription drugs, medical devices and nutrition-health products.
Core capabilities include: automated registration path planning based on product type and indication, real-time NMPA policy tracking with impact assessment, and bilingual document editing with version management. Beta-period data shows the bilingual collaboration feature reduced documentation rework by an average of 40%.
The group plans to open selected platform features to partners in Q3 2026, giving overseas companies real-time visibility into their project registration progress and next actions.
Future updates will continue to focus on compliance, quality and cross-border coordination as key milestones progress.